Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | USP19 | O94966 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7904697 | 0.80 | P2RX7 (0.39) | GAANPC1RAB9AUSP19SLC6A2 | |
| SCHEMBL18391585 | 0.78 | GAA (0.36) | GAANPC1RAB9AUSP19SLC6A2 | |
| SCHEMBL22230513 | 0.78 | GAA (0.40) | GAANPC1RAB9AUSP19SLC6A2 | |
| SCHEMBL12311449 | 0.78 | GAA (0.40) | GAANPC1RAB9A | |
| SCHEMBL14447305 | 0.77 | GAA (0.39) | GAANPC1RAB9AUSP19 | |
| SCHEMBL21000344 | 0.77 | GAA (0.35) | GAANPC1RAB9AUSP19 | |
| SCHEMBL14357416 | 0.77 | GAA (0.39) | GAANPC1RAB9AUSP19 | |
| SCHEMBL772181 | 0.75 | PIK3CD (0.35) | GAANPC1RAB9A | |
| SCHEMBL2619229 | 0.75 | PIK3CD (0.55) | GAANPC1RAB9AUSP19 | |
| SCHEMBL4024910 | 0.75 | GAA (0.38) | GAANPC1RAB9ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354398-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-11-12 | — | — | US | claimed |
| EP-3453714-A2 | CARDENOLIDE AND BUFADIENOLIDE 3-CARBONATE AND 3-CARBAMATE DERIVATIVES FOR THE TREATMENT OF CANCER AND COMPOSITIONS THEREOF | Suzhou Neupharma Co., Ltd (CN) | 2019-03-13 | — | — | EP | claimed |
| CN-103619865-A | Certain chemical entities, compositions, and methods | SUZHOU NEUPHARMA CO LTD | 2014-03-05 | — | — | CN | claimed |
| US-20120196842-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2012-08-02 | — | — | US | claimed |
| EP-0394484-B1 | BENZOTHIADIAZEPINE DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 1995-02-15 | — | — | EP | claimed |
| US-5036065-A | Antiarrythmic agents, anesthetics, calcium antagonists | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-07-30 | — | — | US | claimed |
| EP-0077720-B1 | BIPHENYL ALKYL CARBOXYLATED DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | PIERRE FABRE S.A. (FR) | 1984-07-25 | — | — | EP | claimed |
| US-20200354398-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-11-12 | — | — | US | disclosed |
| EP-3453714-B1 | CARDENOLIDE AND BUFADIENOLIDE 3-CARBONATE AND 3-CARBAMATE DERIVATIVES FOR THE TREATMENT OF CANCER AND COMPOSITIONS THEREOF | SUZHOU NEUPHARMA CO LTD (CN) | 2020-11-04 | — | — | EP | disclosed |
| US-10766920-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200024303-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-01-23 | — | — | US | disclosed |
| US-10344048-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3453714-A2 | CARDENOLIDE AND BUFADIENOLIDE 3-CARBONATE AND 3-CARBAMATE DERIVATIVES FOR THE TREATMENT OF CANCER AND COMPOSITIONS THEREOF | Suzhou Neupharma Co., Ltd (CN) | 2019-03-13 | — | — | EP | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-0394484-B1 | BENZOTHIADIAZEPINE DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 1995-02-15 | — | — | EP | disclosed |
| US-5036065-A | Antiarrythmic agents, anesthetics, calcium antagonists | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-07-30 | — | — | US | disclosed |
| EP-0394484-A1 | BENZOTHIADIAZEPINE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354398-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | GAA 691/4885NPC1 380/4885RAB9A 2171/4885 |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | GAA 374/4885NPC1 1131/4885RAB9A 2410/4885 |
| US-20120196842-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | GAA 691/4885NPC1 380/4885RAB9A 2171/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | GAA 995/4885NPC1 2385/4885RAB9A 3278/4885 |
| US-10766920-B2 | Certain chemical entities, compositions, and methods | TP53, VHL, SGMS2 | GAA 691/4885NPC1 380/4885RAB9A 2171/4885 |
| US-20200024303-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | GAA 691/4885NPC1 380/4885RAB9A 2171/4885 |
| US-10344048-B2 | Certain chemical entities, compositions, and methods | TP53, VHL, SGMS2 | GAA 691/4885NPC1 380/4885RAB9A 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.